An ad-free and cookie-free webpage by FactorPad
Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Taro Pharmaceutical Indus. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.
We show how TARO stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Pharmaceuticals: Generic industry.
Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.
Taro Pharmaceutical Industries Ltd. is engaged in the development, manufacturing, and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada, and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)
Stocks with higher market capitalization often have lower risk. (↑↓)
Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)
Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)
This is a new resource, spread the word, tell a friend